The pioneering work of the Wakefield Research partnership in delivering the COVID-19 PROVENT Antibody Trial has been shortlisted for the Pharma Times’ Clinical Researcher of the Year Awards.

This is fantastic recognition for all partners involved in the PROVENT Antibody Trial, which welcomed the first global patient in November. The team are finalists in the “Clinical Site Team of the Year” category and will now go forward to Stage 3 of the competition, putting clinical research on a national stage in a ‘Finals’ exhibition day in June.

Dr. Nat Wright, Spectrum’s Clinical Research Director, said, “Being recognised through this Pharma Times competition is an amazing opportunity for the Wakefield Together partnership to showcase the value of clinical research in protecting public health. In just 10 weeks, we were able to move this forward at great speed and give local communities a real chance to support the fight against COVID-19. In delivering this project, we also wanted Wakefield to be recognised as a key centre for research and these Awards will help us to do that.”

Together against COVID-19

The eight organisations which comprise the Wakefield Research partnership and helped to successfully deliver the trial are:

  • Spectrum Community Health CIC
  • Mid Yorkshire Hospitals NHS Trust
  • NIHR Clinical Research Network (Yorkshire and Humber)
  • Wakefield Council
  • Bradford and Craven CCG
  • Yorkshire Ambulance Service NHS Trust
  • Connexus Healthcare
  • South West Yorkshire Partnership NHS Foundation Trust

The monoclonal antibodies investigated by the PROVENT Antibody Trial were developed to help prevent COVID-19 infection, as well as to suppress the severity of disease in patients that become infected with the virus. The study was particularly targeted towards people who were extremely vulnerable to COVID-19 (due to immunosuppression or underlying conditions), or at an increased risk of exposure to the virus due to living or working circumstances. Developed before the rollout of licensed COVID-19 vaccinations in the UK and other parts of the world, this trial aimed to recruit around 5000 participants globally.

What next?

The results of the Phase III PROVENT antibody trials are expected to be published soon. If they are successful, the UK Government has an ‘in principle’ agreement which secures access to one million doses of the antibodies.